Kidney Function Tests Market: Market Size & Forecast 2026

Kidney function tests are laboratory diagnostics used to assess how effectively the kidneys filter waste products from the blood, with the most common tests being creatinine, BUN, eGFR, and microalbumin. The global market for these tests was valued at approximately $1.04 billion in 2025 and encompasses reagents, test kits, automated analyzers, and point-of-care devices. These diagnostics serve a critical role across hospitals, clinical laboratories, and outpatient settings for both screening and ongoing disease management. Demand is sustained by the widespread need for routine kidney monitoring among at-risk populations.

• •Market covers creatinine assays, blood urea nitrogen tests, eGFR calculations, and urine albumin screening
• •Reagents and consumables account for the largest revenue share, followed by diagnostic instruments
• •Valued at roughly $1.04 billion in 2025 with consistent historical growth from approximately $845-872 million in 2022-2023

The rising global prevalence of chronic kidney disease, estimated to affect hundreds of millions of people, is the dominant force behind market expansion. Growing rates of diabetes and hypertension, the primary risk factors for kidney damage, have substantially enlarged the population requiring regular renal monitoring. Heightened awareness of kidney health, combined with aging demographics in developed and emerging markets alike, further amplifies testing demand.

• •Diabetes and hypertension epidemics directly drive increased frequency of kidney function assessments
• •Aging populations in North America, Europe, and Asia-Pacific contribute to higher chronic disease incidence and screening rates
• •Public health initiatives promoting early detection of CKD and expanded screening programs are broadening the addressable market

By test type, creatinine and eGFR tests dominate the market due to their widespread clinical adoption, while urinalysis and microalbumin tests occupy smaller but growing niches. Hospitals and independent clinical laboratories represent the primary end-user segments, with point-of-care and home testing gaining modest traction. Geographically, North America leads in market share owing to advanced healthcare infrastructure and high CKD diagnosis rates, while the Asia-Pacific region is emerging as the fastest-growing segment driven by improving diagnostic access and rising disease prevalence.

• •North America commands the largest regional share, supported by high per-capita healthcare spending and strong laboratory networks
• •Asia-Pacific is projected to register the fastest growth, driven by large at-risk populations and expanding diagnostic infrastructure
• •Europe represents a mature market with steady demand shaped by aging demographics and universal screening guidelines

What are the recent trends and outlook?

The market is expected to sustain its 6.5% CAGR, with some projections placing it in the range of $1.5 billion by the early 2030s depending on regional assumptions. Point-of-care kidney testing is gaining momentum as portable devices enable faster results in non-laboratory settings including primary care clinics and patient homes. Growing integration of digital platforms and AI-assisted interpretation tools for complex renal biomarkers represents an emerging trend alongside continued investment in developing economies.

• •Market projected to approach roughly $1.5 billion by the early 2030s based on prevailing CAGR assumptions
• •Point-of-care and home kidney testing devices are gaining adoption, particularly for outpatient and chronic disease management
• •AI-enhanced biomarker interpretation and expanded population screening programs in emerging markets represent key future growth levers